• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞因子和 T 细胞在重症肌无力发病机制中的作用。

Roles of cytokines and T cells in the pathogenesis of myasthenia gravis.

机构信息

Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Department of Neurology, Keio University School of Medicine, Tokyo, Japan.

出版信息

Clin Exp Immunol. 2021 Mar;203(3):366-374. doi: 10.1111/cei.13546. Epub 2020 Dec 3.

DOI:10.1111/cei.13546
PMID:33184844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7874834/
Abstract

Myasthenia gravis (MG) is characterized by muscle weakness and fatigue caused by the presence of autoantibodies against the acetylcholine receptor (AChR) or the muscle-specific tyrosine kinase (MuSK). Activated T, B and plasma cells, as well as cytokines, play important roles in the production of pathogenic autoantibodies and the induction of inflammation at the neuromuscular junction in MG. Many studies have focused on the role of cytokines and lymphocytes in anti-AChR antibody-positive MG. Chronic inflammation mediated by T helper type 17 (Th17) cells, the promotion of autoantibody production from B cells and plasma cells by follicular Th (Tfh) cells and the activation of the immune response by dysfunction of regulatory T (T ) cells may contribute to the exacerbation of the MG pathogenesis. In fact, an increased number of Th17 cells and Tfh cells and dysfunction of T cells have been reported in patients with anti-AChR antibody-positive MG; moreover, the number of these cells was correlated with clinical parameters in patients with MG. Regarding cytokines, interleukin (IL)-17; a Th17-related cytokine, IL-21 (a Tfh-related cytokine), the B-cell-activating factor (BAFF; a B cell-related cytokine) and a proliferation-inducing ligand (APRIL; a B cell-related cytokine) have been reported to be up-regulated and associated with clinical parameters of MG. This review focuses on the current understanding of the involvement of cytokines and lymphocytes in the immunological pathogenesis of MG, which may lead to the development of novel therapies for this disease in the near future.

摘要

重症肌无力(MG)的特征是肌肉无力和疲劳,这是由于存在针对乙酰胆碱受体(AChR)或肌肉特异性酪氨酸激酶(MuSK)的自身抗体引起的。活化的 T、B 和浆细胞以及细胞因子在致病性自身抗体的产生和 MG 神经肌肉接头的炎症诱导中发挥重要作用。许多研究都集中在细胞因子和淋巴细胞在抗 AChR 抗体阳性 MG 中的作用。辅助性 T 细胞 17(Th17)细胞介导的慢性炎症、滤泡辅助性 T(Tfh)细胞促进 B 细胞和浆细胞产生自身抗体以及调节性 T(T)细胞功能障碍激活免疫反应可能导致 MG 发病机制的恶化。事实上,在抗 AChR 抗体阳性 MG 患者中已经报道了 Th17 细胞和 Tfh 细胞数量增加和 T 细胞功能障碍;此外,这些细胞的数量与 MG 患者的临床参数相关。关于细胞因子,白细胞介素(IL)-17;Th17 相关细胞因子、IL-21(Tfh 相关细胞因子)、B 细胞激活因子(BAFF;B 细胞相关细胞因子)和增殖诱导配体(APRIL;B 细胞相关细胞因子)已被报道上调,并与 MG 的临床参数相关。这篇综述重点介绍了细胞因子和淋巴细胞在 MG 免疫发病机制中的作用的最新认识,这可能会导致在不久的将来为这种疾病开发新的治疗方法。

相似文献

1
Roles of cytokines and T cells in the pathogenesis of myasthenia gravis.细胞因子和 T 细胞在重症肌无力发病机制中的作用。
Clin Exp Immunol. 2021 Mar;203(3):366-374. doi: 10.1111/cei.13546. Epub 2020 Dec 3.
2
Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.他克莫司抑制 MuSK 抗体阳性重症肌无力患者的 Th1 和 Th17 反应。
Exp Neurol. 2019 Feb;312:43-50. doi: 10.1016/j.expneurol.2018.11.006. Epub 2018 Nov 22.
3
Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.伴有抗乙酰胆碱受体(AChR)和肌肉特异性激酶(MuSK)抗体的重症肌无力患者的细胞因子差异变化
PLoS One. 2015 Apr 20;10(4):e0123546. doi: 10.1371/journal.pone.0123546. eCollection 2015.
4
Intrathymic Tfh/B Cells Interaction Leads to Ectopic GCs Formation and Anti-AChR Antibody Production: Central Role in Triggering MG Occurrence.胸腺内 Tfh/B 细胞相互作用导致异位 GC 形成和抗 AChR 抗体产生:在触发 MG 发生中的核心作用。
Mol Neurobiol. 2016 Jan;53(1):120-131. doi: 10.1007/s12035-014-8985-1. Epub 2014 Nov 19.
5
Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.肌肉特异性激酶(MuSK)型重症肌无力中CD4和CD8 T细胞反应的特征
J Autoimmun. 2014 Aug;52:130-8. doi: 10.1016/j.jaut.2013.12.005. Epub 2013 Dec 28.
6
An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients.乙酰胆碱受体阳性重症肌无力患者中调节性 T 细胞与辅助性 T 细胞 17 细胞失衡。
Ann N Y Acad Sci. 2018 Feb;1413(1):154-162. doi: 10.1111/nyas.13591. Epub 2018 Jan 24.
7
Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.在肌肉特异性激酶重症肌无力中发现 B 细胞耗竭后产生自身抗体的浆母细胞。
JCI Insight. 2017 Sep 7;2(17). doi: 10.1172/jci.insight.94263.
8
Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.肌肉特异性受体酪氨酸激酶(MuSK)重症肌无力。
Curr Neurol Neurosci Rep. 2016 Jul;16(7):61. doi: 10.1007/s11910-016-0668-z.
9
Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.抗体效应机制在重症肌无力中的作用-神经肌肉接头的发病机制。
Autoimmunity. 2010 Aug;43(5-6):353-70. doi: 10.3109/08916930903555943.
10
CD4 T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS.重症肌无力患者的 CD4 T 细胞表现为 IL-21、IL-4 和 IL-17A 产生增加,以及 PD-1 和 ICOS 的高表达。
Front Immunol. 2020 May 19;11:809. doi: 10.3389/fimmu.2020.00809. eCollection 2020.

引用本文的文献

1
The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis.艾加莫德治疗难治性重症肌无力的疗效和安全性:一项系统评价与荟萃分析
Eur J Med Res. 2025 Aug 20;30(1):775. doi: 10.1186/s40001-025-03057-6.
2
Immune Modulatory Effects of PD-1/PD-L1 in Myasthenia Gravis: Insights From Peripheral Blood Mononuclear Cell Analysis.PD-1/PD-L1在重症肌无力中的免疫调节作用:来自外周血单个核细胞分析的见解
FASEB J. 2025 Aug 15;39(15):e70827. doi: 10.1096/fj.202500887R.
3
Serum cytokine profiles in patients with myasthenia gravis.重症肌无力患者的血清细胞因子谱
Front Neurol. 2025 Jul 3;16:1611673. doi: 10.3389/fneur.2025.1611673. eCollection 2025.
4
Thymic hyperplasia in myasthenia gravis: a narrative review.重症肌无力中的胸腺增生:一篇综述
Mediastinum. 2025 Jun 25;9:17. doi: 10.21037/med-25-12. eCollection 2025.
5
Impact of body mass index on clinical presentation and prognosis in myasthenia gravis.体重指数对重症肌无力临床表现及预后的影响
Orphanet J Rare Dis. 2025 Jul 14;20(1):361. doi: 10.1186/s13023-025-03902-1.
6
Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice.泊维他西普(ALPN - 303;TACI vTD - Fc),一种增强的、强效的BAFF和APRIL双重抑制剂,可改善C57BL/6N小鼠的实验性自身免疫性重症肌无力。
Front Immunol. 2025 Jun 6;16:1533093. doi: 10.3389/fimmu.2025.1533093. eCollection 2025.
7
The role of fatty acid metabolism on B cells and B cell-related autoimmune diseases.脂肪酸代谢在B细胞及B细胞相关自身免疫性疾病中的作用。
Inflamm Res. 2025 Apr 29;74(1):75. doi: 10.1007/s00011-025-02042-3.
8
Serum Inflammatory Factors Levels and Risk of Myasthenia Gravis: A Bidirectional Mendelian Randomization Study.血清炎症因子水平与重症肌无力风险:一项双向孟德尔随机化研究
Mol Neurobiol. 2025 Jun;62(6):7738-7746. doi: 10.1007/s12035-025-04744-5. Epub 2025 Feb 11.
9
Nomogram for predicting pregnancy-related relapse of myasthenia gravis.预测重症肌无力妊娠相关复发的列线图
Orphanet J Rare Dis. 2024 Dec 1;19(1):452. doi: 10.1186/s13023-024-03466-6.
10
Advances in the study of artemisinin and its derivatives for the treatment of rheumatic skeletal disorders, autoimmune inflammatory diseases, and autoimmune disorders: a comprehensive review.青蒿素及其衍生物治疗风湿性骨骼疾病、自身免疫性炎症性疾病和自身免疫性疾病的研究进展:全面综述。
Front Immunol. 2024 Oct 25;15:1432625. doi: 10.3389/fimmu.2024.1432625. eCollection 2024.

本文引用的文献

1
CD4 T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS.重症肌无力患者的 CD4 T 细胞表现为 IL-21、IL-4 和 IL-17A 产生增加,以及 PD-1 和 ICOS 的高表达。
Front Immunol. 2020 May 19;11:809. doi: 10.3389/fimmu.2020.00809. eCollection 2020.
2
IL-37 Represses the Autoimmunity in Myasthenia Gravis via Directly Targeting Follicular Th and B Cells.IL-37 通过直接靶向滤泡性 Th 细胞和 B 细胞抑制重症肌无力的自身免疫。
J Immunol. 2020 Apr 1;204(7):1736-1745. doi: 10.4049/jimmunol.1901176. Epub 2020 Feb 28.
3
Rituximab in AChR subtype of myasthenia gravis: systematic review.Rituximab 治疗重症肌无力乙酰胆碱受体亚型:系统评价。
J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):392-395. doi: 10.1136/jnnp-2019-322606. Epub 2020 Feb 25.
4
Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis.比较眼肌型和全身型重症肌无力患者外周血 B 细胞亚群比值和 B 细胞相关细胞因子水平。
Int Immunopharmacol. 2020 Mar;80:106130. doi: 10.1016/j.intimp.2019.106130. Epub 2020 Jan 21.
5
B Cell Immunophenotyping and Transcriptional Profiles of Memory B Cells in Patients with Myasthenia Gravis.重症肌无力患者记忆B细胞的B细胞免疫表型及转录谱
Exp Neurobiol. 2019 Dec 31;28(6):720-726. doi: 10.5607/en.2019.28.6.720.
6
Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis.小剂量利妥昔单抗治疗对难治性重症肌无力患者 T 及 B 细胞淋巴细胞失衡的影响。
J Neuroimmunol. 2019 Jul 15;332:216-223. doi: 10.1016/j.jneuroim.2019.05.004. Epub 2019 May 9.
7
Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial.硼替佐米治疗抗体介导的自身免疫性疾病(TAVAB):一项单中心、非随机、非安慰剂对照试验的研究方案。
BMJ Open. 2019 Jan 28;9(1):e024523. doi: 10.1136/bmjopen-2018-024523.
8
Il-23/Th17 cell pathway: A promising target to alleviate thymic inflammation maintenance in myasthenia gravis.IL-23/Th17 细胞通路:缓解重症肌无力胸腺炎症维持的有希望的靶点。
J Autoimmun. 2019 Mar;98:59-73. doi: 10.1016/j.jaut.2018.11.005. Epub 2018 Dec 18.
9
Immunotherapy in myasthenia gravis in the era of biologics.免疫疗法在生物制剂时代的重症肌无力。
Nat Rev Neurol. 2019 Feb;15(2):113-124. doi: 10.1038/s41582-018-0110-z.
10
Regulatory B cells in myasthenia gravis are differentially affected by therapies.重症肌无力中的调节性B细胞受治疗的影响存在差异。
Ann Clin Transl Neurol. 2018 Sep 22;5(11):1408-1414. doi: 10.1002/acn3.645. eCollection 2018 Nov.